Hard to ignore this channel in Medtronic. 43 year dividend growth streak with 23% debt to cap and a payout ratio of 44%. Yield theory, this is the highest the yield for Medtronic has been for a while, so I think that indicates a great time to long in an investment portfolio. Forward P/E is below the 5 year average as well, but I'm honestly more interested in the...
Earnings growth is slowing. Forward looking earnings growth is around 8% if you include a 9-11% loss of EPS in 2022. 18.44% growth in 2023, 14% expected in 2024. Still an advertising juggernaut. Blended P/E of about 16 is incredibly low. It seems like it'll resume a more consistent growth after this hiccup. I think it'll start trading closer to a 20 P/E in the...
Price action compared to an adjusted earnings growth rate of about 43% with forward looking EPS growth of 24% in 2023 and 20% in 2024. Current blended P/E is about 24, which is close to the expected growth in the next few years
Risk is 84 LT debt to cap. Company has been repurchasing stock, though which is nice.
ST bearish. Seems overextended with lower momentum. MT and LT unclear; oil is a rough one with a lot of geopolitical influences.
Forecasted 5.15 EPS 2022
Norm P/E 13.23
Valuation Estimate ~68 based on 2022 forecast. But keep in mind that growth is forecasted to stall after, so around 60 is probably more appropriate.
Value based on 2021 EPS would...
Top pharma pick right now other than BMY. P/E 13.11 with forecasted 6-7% earnings growth and an EPS yield of 7.62%.
Historic Norm P/E 18.89
^ 10 Y = 14.50
^ 5 Y = 14.25
3.49% Div payer.
Valuation estimate based on 2023 forecasted EPS (19.11) and P/E of 14.25 = $272.32
Sitting at 3.32% yield and 8.62 P/E (norm is 18.65 and 5Y norm is 11.17) with earnings growth rate approx. 6.18% since 2000 but has increased to 15-16% if you look at the 10Y and 5Y norms.
Estimates are for about 4-6% the next 2 years.
A+ Credit Rating
48LT Debt to Cap
PT $96 by 2023 using a 7% earnings growth rate and 12 P/E
DuPont spinoff with 4.57% div yld and blended P/E of 7 versus normal of 18. With 28% forecasted drop in EPS into 2022, this would still give about a 118 target based on the normal P/E. This would be a 96ish target based on a P/E of about 15.
Slow growth, but it makes sense as an income play.
Technicals are neutral. Fundamentals are great.
Earnings growth of 11% (8% forecasted) with P/E at 9.70. Historic norm is 11.70, so it historically trades pretty cheap.
Dividend yield of 2.65% is about in line with average.
7.20 P/OCF versus Normal P/OCF of 8.00. Small decline in OCF expected, but growth of EPS is better imo.
Adjusted P/E is a little expensive right now (29.64 v. 30 norm 5Y and 23 Norm 10Y).
With yield theory, it's at the yield that it was at in 2016, which is attractive.
With OCF, it's at fair value with Blended P/OCF 18 vs. 5Y 17.97.
OCF growth rate 7.6%. Earnings growth rate 10%.
It's perfectly fine. DOW and CC might look better. Bottom of the channel is a solid...
Short side goal would be for this to be a rounding top - it just wouldn't be finished yet.
Neutral on fundamentals (5Y P/E 9.49 vs. 9.26 now). Compare to lifetime P/E norm of 8.88, it might be a tiny bit expensive but not a lot.
OCF is a little cheap relative, but expected 25% drop in 2022 (5Y OCF 25 vs. 10.89 OCF now). Forecast has basically no growth.
5Y P/E 27.71 - Now P/E 29.87.
Adjusted Earnings Growth of 7.96% with div @ 1.57%
More attractive equity based on OCF
5Y Norm P/OCF = 13.59
Now P/OCF ~14
Adj growth OCF = 6.67%
WM has a pretty wide moat.
Adjusted Earnings Growth Rate about 14.74% with Blended P/E of 11.31.
Normal P/E is 20.35, forecasts are decently accurate and expect future 10-15% growth YoY. EPS Yld is 8%.
I think Tapestry is a steal here. 2.70% dividend that doesn't necessarily grow, but it is well covered by cash flow.
Owns Coach, Spade, Weitzman.
Consistent 15% growth puts the company...
Leidos = probably my favorite. Their global across 30 countries and work in aviation, defense, energy, healthcare, AI, science (environmental science, electronic warfare, sensors, autonomous systems, life sciences), space (historically long term contracts w/ NASA), and surface transportation (so freight and logistics, vehicle safety, automated vehicles)